<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="48557">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02474082</url>
  </required_header>
  <id_info>
    <org_study_id>CAIN457ADE06</org_study_id>
    <nct_id>NCT02474082</nct_id>
  </id_info>
  <brief_title>Study of Secukinumab Compared to Fumaderm® in Adults With Moderate to Severe Psoriasis.</brief_title>
  <acronym>PRIME</acronym>
  <official_title>A Randomized, Controlled, Multicenter, Open-label Study With Blinded Assessment of the Efficacy of Subcutaneous Secukinumab Compared to Fumaderm® in Adults With Moderate to Severe Plaque Psoriasis.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, controlled, multicenter, open-label study with blinded assessment of
      the efficacy of subcutaneous secukinumab compared to Fumaderm®, in 200 adults with moderate
      to severe plaque type psoriasis who are candidates for systemic therapy. The study consists
      of 2 periods: a screening period of at least one week and up to four weeks, and a treatment
      period of 24 weeks. During the screening period eligibility of the patients is confirmed.
      Eligible patients are randomized 1:1 to treatment arm A or B at week 0. Patients in
      treatment arm A receive secukinumab administered at weeks 0, 1, 2, 3, 4, 8, 12, 16 and 20
      and are followed up for assessments of the study endpoints until week 24. Patients in
      treatment arm B receive daily doses of Fumaderm® p.o.. Safety and efficacy measurements of
      secukinumab and Fumaderm® will be performed throughout the study and up to week 24.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2015</start_date>
  <completion_date type="Actual">June 2016</completion_date>
  <primary_completion_date type="Actual">June 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single Blind (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients achieving PASI 75 at week 24</measure>
    <time_frame>24 weeks</time_frame>
    <description>To demonstrate the superiority of secukinumab compared to Fumaderm® in subjects with moderate to severe plaque psoriasis based on the proportion of PASI 75 responders at Week 24.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Absolute PASI scores and number of patients achieving PASI 50/75/90/100</measure>
    <time_frame>at weeks 1, 2, 3, 4, 6, 8, 12, 16, 20 and 24.</time_frame>
    <description>To compare efficacy of secukinumab and Fumaderm® on raw PASI and PASI 50/75/90/100 response rates at weeks 1, 2, 3, 4, 6, 8, 12, 16, 20 and 24.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BSA</measure>
    <time_frame>at weeks 1, 2, 3, 4, 6, 8, 12, 16, 20 and 24.</time_frame>
    <description>To compare efficacy of secukinumab and Fumaderm® on BSA at weeks 1, 2, 3, 4, 6, 8, 12, 16, 20 and 24.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IGA mod 2011</measure>
    <time_frame>at weeks 1, 2, 3, 4, 6, 8, 12, 16, 20 and 24.</time_frame>
    <description>To compare efficacy of secukinumab and Fumaderm® on IGA mod. 2011 and IGA mod. 2011 0/1-response at weeks 1, 2, 3, 4, 6, 8, 12, 16, 20 and 24.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DLQI and number of patients achieving DLQI 0/1</measure>
    <time_frame>at weeks 1, 2, 3, 4, 6, 8, 12, 16, 20 and 24.</time_frame>
    <description>To compare the effect of secukinumab and Fumaderm® on DLQI and DLQI 0/1 response at weeks 1, 2, 3, 4, 6, 8, 12, 16, 20 and 24.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SF-36</measure>
    <time_frame>at weeks 1, 2, 3, 4, 6, 8, 12, 16, 20 and 24.</time_frame>
    <description>To compare the effect of secukinumab and Fumaderm® on SF-36 response at weeks 1, 2, 3, 4, 6, 8, 12, 16, 20 and 24.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NAPSI</measure>
    <time_frame>at weeks 1, 2, 3, 4, 6, 8, 12, 16, 20 and 24.</time_frame>
    <description>To compare the effect of secukinumab and Fumaderm® on NAPSI response at weeks 1, 2, 3, 4, 6, 8, 12, 16, 20 and 24.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">202</enrollment>
  <condition>Psoriasis</condition>
  <arm_group>
    <arm_group_label>Secukinumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in treatment arm A will receive a dose of 300 mg secukinumab administered as 2 subcutaneous injections of 150 mg in a SensoReady pen (i.e. 2 x 150 mg) at weeks 0, 1, 2, 3, 4, 8, 12, 16 and 20.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fumaderm®</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Week 0: 1 tablet of Fumaderm® INITIAL in the evening Week 1: 1 tablet Fumaderm® INITIAL, in the morning and evening Week 2: 1 tablet Fumaderm® INITIAL in the morning, at noon and in the evening until the last tablet of a 40-tablet-blister is consumed Week 2-3: At the day after the last tablet of the Fumaderm® INITIAL 40-tablet-blister is consumed and through week 3, 1 tablet of Fumaderm® in the evening Week 4: 1 tablet Fumaderm® in the morning and evening Week 5: 1 tablet Fumaderm® in the morning, at noon and in the evening Week 6: 1 tablet of Fumaderm® in the morning and at noon, 2 tablets of Fumaderm® in the evening Week 7: 2 tablets of Fumaderm® in the morning, 1 tablet of Fumaderm® at noon, 2 tablets of Fumaderm® in the evening Week 8-24: 2 tablets of Fumaderm® in the morning, at noon and in the evening</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Secukinumab</intervention_name>
    <description>Secukinumab 150 mg, 1 ml liquid formulation in a pre-filled pen for s.c. injection</description>
    <arm_group_label>Secukinumab</arm_group_label>
    <other_name>AIN457</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fumaderm®</intervention_name>
    <description>Fumaderm® INITIAL, gastro-resistant tablets 30 mg dimethylfumarate, 67 mg ethylhydrogenfumarat calcium salt, 5 mg ethylhydrogenfumarat magnesium salt, 3 mg ethylhydrogenfumarat zinc salt Fumaderm®, gastro-resistant tablets 120 mg dimethylfumarate, 87 mg ethylhydrogenfumarat calcium salt, 5 mg ethylhydrogenfumarat magnesium salt, 3 mg ethylhydrogenfumarat zinc salt</description>
    <arm_group_label>Fumaderm®</arm_group_label>
    <other_name>Fumarate, Fumaric acid, Fumaric acid esters</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men or women must be at least 18 years of age at the time of screening

          -  Chronic plaque-type psoriasis diagnosed for at least 6 months before randomization
             Patients with moderate to severe plaque psoriasis who are candidates for systemic
             therapy as defined at randomization by:

          -  PASI score of &gt;10

          -  Affected body surface area (BSA) &gt; 10%

          -  DLQI &gt;10

          -  Inadequate response, intolerance or contraindication to topical psoriasis treatment
             as documented in the patient's medical history or reported by the patient or
             determined by the investigator at screening.

        Exclusion Criteria (abbreviated):

          -  Previous systemic treatment of plaque psoriasis or known contraindication for
             systemic therapy at baseline

          -  Ongoing use of other prohibited psoriasis and non-psoriasis treatment.

          -  Clinically important active infections or infestations, chronic, recurrent or latent
             infections or infestations

          -  Patients with severe liver diseases

          -  Patients with severe gastrointestinal diseases including but not limited to
             ventricular and duodenal ulcers

          -  Patients with severe kidney diseases or serum creatinine above 1 x ULN

          -  Patients with known hematological disease or lab abnormalities

          -  Pregnancy, breast feeding, or unwillingness/inability to use appropriate measures of
             contraception (if necessary)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bad Bentheim</city>
        <zip>48455</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Berlin</city>
        <zip>10247</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Berlin</city>
        <zip>10789</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Berlin</city>
        <zip>13187</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Berlin</city>
        <zip>13578</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bielefeld</city>
        <zip>33647</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bochum</city>
        <zip>44791</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bochum</city>
        <zip>44803</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bonn</city>
        <zip>53105</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Darmstadt</city>
        <zip>64283</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Erlangen</city>
        <zip>91054</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Essen</city>
        <zip>45147</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Frankfurt</city>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Gera</city>
        <zip>07548</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Halle</city>
        <zip>06108</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hamburg</city>
        <zip>20354</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hamburg</city>
        <zip>22391</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kiel</city>
        <zip>24105</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lubeck</city>
        <zip>23538</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ludwigshafen</city>
        <zip>67063</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Mannheim</city>
        <zip>68167</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Muenchen</city>
        <zip>81675</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Muenster</city>
        <zip>48149</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Osnabruck</city>
        <zip>49074</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Quedlinburg</city>
        <zip>06484</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Schwerin</city>
        <zip>19055</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Selters</city>
        <zip>56242</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Stade</city>
        <zip>21682</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>September 2016</verification_date>
  <lastchanged_date>September 23, 2016</lastchanged_date>
  <firstreceived_date>April 16, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Antibodies, Monoclonal</mesh_term>
    <mesh_term>Dimethyl Fumarate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
